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Many muscular and neurological disorders are associated
with mitochondrial dysfunction and are often accompanied by
changes in mitochondrial morphology. Mutations in the gene
encoding OPA1, a protein required for fusion of mitochondria,
are associated with hereditary autosomal dominant optic atro-
phy type I. Herewe show thatmitochondrial fragmentation cor-
relates with processing of large isoforms of OPA1 in cybrid cells
from a patient with myoclonus epilepsy and ragged-red fibers
syndrome and in mouse embryonic fibroblasts harboring an
error-prone mitochondrial mtDNA polymerase . Further-
more, processed OPA1 was observed in heart tissue derived
fromheart-specific TFAMknock-outmice suffering frommito-
chondrial cardiomyopathy and in skeletalmuscles frompatients
suffering from mitochondrial myopathies such as myopathy
encephalopathy lactic acidosis and stroke-like episodes. Dissi-
pation of the mitochondrial membrane potential leads to fast
induction of proteolytic processing of OPA1 and concomitant
fragmentation of mitochondria. Recovery of mitochondrial
fusion depended on protein synthesis and was accompanied by
resynthesis of large isoforms of OPA1. Fragmentation of mito-
chondria was prevented by overexpressing OPA1. Taken
together, our data indicate that proteolytic processing of OPA1
has a key role in inducing fragmentation of energetically com-
promised mitochondria. We present the hypothesis that this
pathway regulates mitochondrial morphology and serves as an
early response to prevent fusion of dysfunctional mitochondria
with the functional mitochondrial network.
Mitochondria fulfill a number of essential functions in the
eukaryotic cell. One such process is oxidative phosphorylation,
a process that generates the vast majority of cellular ATP.
Therefore, it is not surprising that many muscular and neuro-
logical disorders, various forms of cancer, diabetes, obesity, and
aging, are associated with mitochondrial dysfunction (1–6).
Interestingly, in many of these diseases or conditions aberrant
mitochondrial morphologies are observed (1, 7). Mitochondria
in numerous cell types form a large network of interconnected
tubules that is maintained by a balance of fission and fusion
events (8, 9). Deficiencies in mitochondrial fusion and fission
play an important role in various neurodegenerative diseases
such as Charcot-Marie-Tooth disease type 2A and 4A, and
optic atrophy type 1 (10–13). Furthermore, these dynamic pro-
cesses apparently are crucial for the cell, e.g. in apoptosis (14–
18), formation of dendritic spines and synapses (19, 20), and
functional complementation of mtDNA mutations by content
mixing (21, 22). Fusion of mitochondria, in particular of the
inner mitochondrial membrane, depends on the presence of a
mitochondrial membrane potential (23–26). Still it is unclear
how mitochondrial dysfunction and fragmentation of mito-
chondria are linked on a molecular level. Here we report on a
major molecular player, namely OPA1, in this process.
Mutations in the OPA1 gene are known to cause hereditary
autosomal dominant optic atrophy type I, the most prevalent
hereditary neuropathy of the optic nerve occurring with a prev-
alence of 1:12,000 to 1:50,000, depending on the population (10,
11). The OPA1 protein is required for mitochondrial fusion
(27–29). Overexpression of OPA1 inmouse embryo fibroblasts
promotes tubulation of mitochondria (28). Down-regulation of
OPA1 leads to fragmentation of mitochondria, mitochondrial
dysfunction, altered mitochondrial inner membrane morphol-
ogy, and increased propensity for apoptosis (15, 18, 27, 29, 30).
Eight alternatively spliced mRNAs transcribed from the OPA1
gene and several tissue-specific isoforms of the OPA1 protein
were described (31, 32). The ortholog of OPA1 in bakers’ yeast,
Mgm1, is essential formitochondrial fusion (33, 34) and is pres-
ent in two proteolytically matured isoforms, l-Mgm1 and
s-Mgm1, both of which are required for function (35). Forma-
tion of s-Mgm1 depends on an ATP-dependent mechanism
termed alternative topogenesis (36). Therefore, the bioener-
getic state of mitochondria was proposed to be linked to their
morphology. Here we report that in mouse and human the
orthologous protein OPA1 has a key role in linking the bioen-
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ergetic state of mitochondria to mitochondrial morphology,
albeit in a mechanistically distinct manner.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—HeLa cells, human fibroblasts,
immortalized mouse embryonic fibroblast from control
(mouse embryonic fibroblast cell lines 13 and 14) and mutator
mice (mouse embryonic fibroblast cell lines 2 and 7) (37, 38)
and cybrid cell lines (pT1 and pT3) (39) were grown under
standard conditions in Dulbecco’s modified Eagle’s medium
containing 4.5 g/liter glucose and 2 mM L-glutamine supple-
mentedwith 10% fetal bovine serum, 50 units/ml penicillin, and
50 g/ml streptomycin. Cell culture reagents were obtained
from PAA Laboratories (Co¨lbe, Germany); CCCP,2 o-phenan-
throline, and cycloheximide were purchased from Sigma, and
phenylmethylsulfonyl fluoride was from Serva (Germany). The
plasmidpMSCV-Opa1, encoding amouse variant ofOPA1corre-
sponding to human spliceform 1, was a kind gift of Luca Scorrano
(Padova, Italy) (28). TheDRP1K38EN-terminally fused to cyan flu-
orescent protein (pECFP-C1-DVLPK38E) andmitochondrially tar-
getedGFP plasmids (pcDNA3-OCT:GFP) were kind gifts ofHeidi
McBride (Ottawa Heart Institute, Canada). Transient transfec-
tions of HeLa cells were performed using Metafectene (Biontex
Laboratories,Germany)orFuGENEHD(RocheAppliedScience).
Tissue Samples—Heart tissue was obtained from heart-spe-
cific TFAM knock-out mice as described earlier (40). Skeletal
muscle biopsies were derived from patients diagnosedwith res-
piratory chain disorders (patients 1–10) or control patients
(control patients A–D) with no such defects. Informed consent
was given by all patients. Patients 1–10 included in this study
were previously diagnosedwith respiratory chain disorders suf-
fering from mitochondrial encephalomyopathies or isolated
myopathies on the basis of clinical, biochemical, morphologi-
cal, and, in some cases, genetic findings. The activities of the
respiratory chain complexes of all control patients were within
the normal range. Measurements of rotenone-sensitive
NADH-ubiquinone oxidoreductase (complex I), succinate-cy-
tochrome c oxidoreductase (complexes II and III). and cyto-
chrome c oxidase (complex IV) were determined spectropho-
tometrically in skeletal muscle homogenates according to
Fischer et al. (41). Activities were expressed as units per gram of
noncollagenous protein and related to the mitochondrial marker
enzymecitrate synthase.Homogenates fromskeletalmuscle biop-
sies were analyzed byWestern blotting, and band intensities were
determined densitometrically from the immunoblot.
Antibodies—Anti-OPA1 antibodies were affinity-purified
from a rabbit polyclonal serum raised against the C terminus of
human OPA1 using the synthetic peptide CDLKKVREIQEK-
LDAFIEALHQEK (Pineda Antiko¨rper-Service, Berlin). Anti-
bodies against humanMIA40 were raised in rabbits using puri-
fiedMIA40 fused tomaltose-binding protein. Polyclonal rabbit
sera against hTim23 and hTim44 were raised as described pre-
viously (42). Mouse anti cytochrome c (clone 7H8.2C12; BD
Biosciences), anti-DRP1 (DLP1 clone 8; BD Biosciences), and
anti--actin (clone AC-15; Sigma)monoclonal antibodies were
used for immunoblotting. The goat anti-AIF (D-20) and rabbit
anti-Fis1 sera were purchased from Santa Cruz Biotechnology
and IMGENEX, respectively. The anti-Mfn2 serum was a kind
gift of Antonio Zorzano (University of Barcelona, Spain).
Fluorescence Microscopy—Live cells were fluorescently
labeled with MitoTracker Red CMXRos (Molecular Probes)
for mitochondria or with 4,6-diamidino-2-phenylindole dihy-
drochloride (Molecular Probes) for the nucleus after fixation
and permeabilization. Immunostaining was carried out with
mouse anti-cytochrome cmonoclonal antibody (clone 6H2.B4;
BD Biosciences) and chicken anti-GFP antibody (Aves Lab
Inc.). The following secondary antibodies conjugated to fluo-
rescent dyes were used: Alexa Fluor 488 goat anti-mouse IgG
(HL) (Molecular Probes), Cy3-conjugated donkey anti-
mouse IgG (HL), and fluorescein isothiocyanate-conjugated
donkey anti-chicken IgG (Jackson ImmunoResearch). Cells
weremountedwith ProlongGold antifade reagent (Molecular
Probes). All treatments were done according to the manufac-
turers’ instructions. Mitochondrial morphology was analyzed
by confocal microscopy using a Zeiss LSM 510 (Carl Zeiss
Microscopy, Jena, Germany) equipped with a 63 objective.
For all imaging, 512 512pixel images of single confocal planes
were acquired and processed with the Bitplane Imaris 4 soft-
ware. At least 100 cells were analyzed for each slide of each
2 The abbreviations used are: CCCP, carbonyl cyanide 3-chlorophenylhydra-
zone; GFP, green fluorescent protein; MERRF, myoclonus epilepsy and
ragged-red fibers syndrome; CHX, cycloheximide; MELAS, myopathy
encephalopathy lactic acidosis and stroke-like episode.
FIGURE 1. MERRF cybrid cells show fragmentation of mitochondria and
alterations in OPA1 isoforms.MERRF and control cybrid cell lines were cul-
tured, stained with MitoTracker (red), fixed, and either immunostained
against cytochrome c (green) or stained with 4,6-diamidino-2-phenylindole
dihydrochloride (blue). a, merged confocal fluorescence images are shown.
Top, overview (scale bar, 20 m); bottom, indicated box (scale bar, 10 m).
b, quantification of mitochondrial morphology in cells: tubular, at least one
mitochondrial tubule of 5mormore; intermediate, at least one between 0.5
and 5 mbut none more than 5 m; fragmented, none of more than 0.5 m
in length. c, OPA1 isoforms in Western blot analysis of total cell extracts.
c, HeLa cell extracts are shown for comparison.
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condition or cell line. Error bars represent standard deviations
calculated from three to five slides.
Pulse-Chase Experiments—HeLa cells were seeded on 6-well
plates (105 cells per well). One day later, the cells were washed
two times with phosphate-buffered saline and starved for 30
min in Dulbecco’s modified Eagle’s medium without sodium
pyruvate, L-methionine, and L-cystine (Invitrogen). Pulse label-
ing was started by addition of the metabolic labeling reagent
(Tran35S-label, MP Biochemicals Europe), and cells were incu-
bated for 2 h 30 min, washed twice with phosphate-buffered
saline, and either harvested at that time point or incubated fur-
ther with complete Dulbecco’s modified Eagle’s medium sup-
plementedwith 10% fetal bovine serum, harvested, lysed in lysis
buffer (0.5% Triton X-100, 150 mM NaCl, 10 mM Tris/HCl, 5
mM EDTA, supplemented with complete protease inhibitor
mixture purchased from Roche Applied Science), and submit-
ted to immunoprecipitation with OPA1 antibodies and protein
A-Sepharose CL-4B beads (Amersham Biosciences). Preim-
mune serumwas used in control experiments. The elution frac-
tions of the different immunoprecipitation experiments were
analyzed byWestern blotting and digital autoradiography after
SDS-PAGE using the same membrane.
Subcellular Fractionation of Cells—Cells were harvested,
washed in phosphate-buffered saline supplemented with 5 mM
EDTA, and resuspended in 1ml of RSBbuffer (10mMHEPES (pH
7.5), 1 mM EDTA, 210 mM mannitol, 70 mM sucrose, supple-
mentedwithcompleteprotease inhibitormixture).Cellswerebro-
ken by six passages through a 26-gauge needle fitted to a 5-ml
syringe. Cell pellets from low speed centrifugations (2,000 g, 10
min, 4 °C) were resuspended in RSB buffer and passaged again
through a needle as described. This stepwas repeated 3 to 4 times.
The supernatants from lowspeedcentrifugationswerepooledand
centrifugedagain (13,000 g, 10min, 4 °C) toobtainacrudemito-
chondrial pellet and a cytosolic supernatant.
RESULTS
MERRF Cybrid Cells Show Fragmentation of Mitochondria
and Alterations in OPA1 Isoforms—In a first approach to study
the molecular mechanism of fragmentation of mitochondria in
FIGURE 2.Mutator mouse embryonic fibroblasts show fragmentation of
mitochondria and alterations in OPA1 isoforms. Immortalized mouse
embryonic fibroblasts from two control mice and two mutator mice were
cultured, stained with MitoTracker (red), fixed, and either immunostained
against cytochrome c (green) or stained with 4,6-diamidino-2-phenylindole
dihydrochloride (blue). a, merged confocal fluorescence images are shown.
Top, overview (scale bar, 20 m); bottom, indicated box, (scale bar, 10 m).
b, quantification of mitochondrial morphology as in Fig. 1b. c,OPA1 isoforms
in Western blot analysis of total cell extracts. FIGURE 3. Patterns of OPA1 isoforms are altered in tissue samples exem-
plary of mitochondrial dysfunction. a, Western blot analysis of OPA1 iso-
formsofheart tissue frommicewithaheart-specific knock-outof TFAM(TFAM
ko) at 4 or 8 weeks age and of control mice. b, homogenates from skeletal
muscle biopsies from control individuals (A–D) and from patients suffering
from respiratory disorders (patients 1–10, see Table 1) analyzed by Western
blotting for OPA1. The smallest form of OPA1 detected is indicated by an
arrow. c, relative amounts of the smallest OPA1 isoform of all OPA1 isoforms
determined densitometrically from b and from HeLa cells treated or not for
6 h with CCCP (Fig. 4b, two left lanes).
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human diseases, we investigated the role of fusion-promoting
OPA1 in a cybrid cell line derived from a MERRF patient suf-
fering from severe myopathy (39). The mtDNA in the cell line
contained the A8344G mutation in the tRNALys in a nearly
homoplasmic manner leading to a substantial impairment of
mitochondrial function (39). The cells from the MERRF
patient, but not control cells, showed highly fragmented mito-
chondria (Fig. 1,a and b). The pattern of the five detectedOPA1
protein isoformswas altered in theMERRF cells comparedwith
control cells (Fig. 1c). It appears that in the MERRF cells the
larger isoforms are reduced compared with the smallest iso-
form of OPA1. As OPA1 is required for mitochondrial fusion,
the observed loss of large OPA1 isoforms may explain the frag-
mentation of mitochondria in this model system of mitochon-
drial dysfunction.
Mutator Mouse Embryonic Fibroblasts Show Fragmentation
ofMitochondria and Alterations in OPA1 Isoforms—To further
substantiate this, we analyzed immortalized mouse embryonic
fibroblasts derived from the so-called “mutatormouse” (37, 38).
This mouse was generated by a homozygous knock-in of a var-
iant of mtDNA polymerase  resulting in a phenotype of pre-
mature aging. The variant enzyme has much reduced proof-
reading activity, and mtDNA accumulates random point
mutations at a 3–5-fold higher rate than normal leading to
severe mitochondrial dysfunction. Mitochondria were exten-
sively fragmented inmutator but not in control cell lines (Fig. 2,
a and b). The levels of the larger OPA1 isoforms were strongly
reduced, whereas the levels of the smaller forms were increased
in the mutant cells (Fig. 2c). These findings suggest that muta-
tions in mtDNA are causative to changes in OPA1 isoform lev-
els and mitochondrial fragmentation.
Patterns of OPA1 Isoforms Are Altered in Tissue Samples
Exemplary of Mitochondrial Dysfunction—TFAM is an essen-
tial mitochondrial transcription factor also required for
mtDNA maintenance. A heart-specific knock-out of TFAM in
mice led to a severe depletion of mtDNA in the heart, resulting
in cardiomyopathy and altered mitochondrial morphology
(40). The pattern ofOPA1 isoforms in heart tissue of thesemice
was changed as compared with controls; the abundance of
larger OPA1 isoforms was reduced, whereas that of smaller
isoforms was increased (Fig. 3a). This was even more pro-
nounced at 8 weeks compared with 4 weeks of age (Fig. 3a),
consistent with the progression of the cardiomyopathy in those
mice (40). This shows thatmitochondrial dysfunction resulting
from mtDNA depletion is linked to the reduction of larger
OPA1 isoforms in the affected tissue.Moreover, the alterations
of mitochondrial morphology observed earlier by electron
microscopy (40) are likely because of the shift in the levels of
OPA1 isoforms.
In addition, we checked whether alterations in the OPA1
isoform pattern are detectable in patients diagnosed with res-
piratory chain defects. Indeed, an increase of smaller OPA1
isoforms was observed in skeletal muscle from these patients
but not from controls (Fig. 3b). This was quantified by deter-
mining the ratios of the amounts of the smallest OPA1 isoform
(arrow in Fig. 3b) to the total of all OPA1 isoforms (Fig. 3c).
Besides the shift patients exhibited a much broader variation
comparedwith controls. The patientswithmitochondrial DNA
depletion syndromes or harboring a MELAS mutation were
among those with the highest ratios (Fig. 3c, patients 1 and 7
andTable 1). In none of the controls didwe observe such a shift.
We conclude that OPA1 isoforms are altered in patients with
mitochondrial disorders, in particular those with depletion of
or mutations in mtDNA.
Dissipation of the Membrane Potential Leads to Mitochon-
drial Fragmentation and to Proteolytic Conversion of Larger
into Smaller Isoforms of OPA1—Next we asked whether dissi-
pation of the membrane potential is sufficient to trigger
changes in the abundance of OPA1 isoforms and whether this
coincides with fragmentation of mitochondria. Indeed, treat-
ment of HeLa cells or fibroblasts with the uncoupler CCCP led
to fragmentation of mitochondria (Fig. 4a; data not shown)
consistent with earlier reports (23, 25, 26). Furthermore, this
coincided with a dramatic shift of OPA1 isoforms toward the
smaller isoforms (Figs. 3c and 4b). A similar behavior was
reported recently in another study performed in parallel (43).
Processing is specific to OPA1 as other known fusion and fis-
sion components such as Mfn2, Drp1, and Fis1 are not pro-
TABLE 1
Genetic and biochemical analysis of mitochondrial function in skeletal muscle biopsies from patients and controls
Patients 1–10 included in this study were previously diagnosed with respiratory chain disorders. A–D represent control patients without such disorders. The activities of
the respiratory chain complexes (I to IV) of all controls and patients were determined in skeletal muscle homogenates and are expressed in percent of the lowest limit of the
respective reference range. The genetic defect causing the disease is indicated when known. Homogenates from skeletal muscle biopsies were analyzed byWestern blotting
for OPA1 pattern (Fig. 3b). The relative amount of the smallest detected form ofOPA1 of all OPA1 isoformswas determined densitometrically from the immunoblot of Fig.
3b. The values of this ratio are indicated here and plotted in Fig. 3c.MELAS indicates myopathy encephalopathy lactic acidosis and stroke-like episodes.
Samples Respiratory chain enzyme activities Genetics Relative amount of smallestOPA1 isoform of total
%
A Normal 6.7
C Normal 7.5
B Normal 10.7
D Normal 14.7
5 I, 10% Unknown 14.7
9 I, 80% II/III, 40% IV, 20% Unknown 16.3
2 IV, 20% Unknown 17.3
8 I, 70% II/III, 60% IV, 10% A1541G mutation in SCO2 18.7
6 I, 30% Unknown 22.1
4 I, 30% IV, 30% mtDNA depletion 22.7
3 I, 30% II/III, 80% IV, 30% Unknown 22.9
10 I, 50% II/III, 50% IV, 20% mtDNA depletion 23.5
7 I, 50% II/III, 50% IV, 80% MELAS A3243G mutation in tRNA-Leu(UUR) 39.7
1 I, 50% II/III, 50% IV, 20% mtDNA depletion 51.2
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cessed (Fig. 4c). To test whether the two larger OPA1 isoforms
are converted into the smaller ones upon dissipation of the
membrane potential, we performed metabolic, radioactive
pulse labeling of HeLa cells followed by a chase in the absence
or presence of CCCP for 1 h. We could confirm that indeed
the two larger OPA1 isoforms (L1- and L2-OPA1) are con-
verted into the smaller ones (S3-, S4-, and S5-OPA1), in partic-
ular into S3- and S5-OPA1 (Fig. 4d). This is apparently
because of proteolytic cleavage of the larger forms because
this process was blocked in the presence of the protease
inhibitor o-phenanthroline (Fig. 4e). Processing of OPA1
occurs within mitochondria because all OPA1 isoforms
detected remain in the mitochondrial fraction and are not
released to the cytosol after subcellular fractionation (Fig.
4f). Furthermore, the smaller isoforms produced could be
extracted from mitochondria with detergent-free buffer
with a higher efficiency than the larger forms suggesting that
the larger forms are integral membrane protein isoforms,
and the shorter ones are only peripherally attached to the
membrane (Fig. 4g). Other mitochondrial proteins, includ-
ing three intermembrane space proteins (cytochrome c, AIF,
and hMIA40), are not processed supporting further that
processing is specific for OPA1 (Fig. 4, f and g). Fragmenta-
tion of mitochondria occurred rapidly within 15–30 min
after addition of CCCP (Fig. 5, a and b). This is because of a
block inmitochondrial fusion as shown earlier (23, 26). Proc-
essing of OPA1 took place within the same narrow time
frame (Fig. 5c). Impairment of fusion of mitochondria may
therefore be due to rapid inactivation of OPA1 by proteolysis
of larger isoforms. Moreover, upon removal of CCCP, nor-
mal mitochondrial morphology was recovered, and this
coincided with the reappearance of larger isoforms of OPA1
(Fig. 5, a–c). Mitochondrial fragmentation and OPA1 proc-
essing are not accompanied by cytochrome c release in this
or in any of the investigated models of mitochondrial dys-
function (Figs. 1a, 2a, and 4e and data not shown). This
suggests that mitochondrial fragmentation per se does not
result in apoptosis consistent with an earlier report (15).
Mitochondrial Fragmentation and OPA1 Processing Are
Causally Linked—Mitochondrial fragmentation after dissipa-
tion of the membrane potential is not dependent on protein
synthesis, whereas recovery of mitochondrial fusion after rees-
tablishing a membrane potential is (26). We asked whether
OPA1 processing and resynthesis of OPA1 isoforms, respec-
FIGURE 4.Dissipation of themembrane potential inducesmitochondrial
fragmentation and concomitant OPA1 processing withinmitochondria.
a,HeLa cells were treatedwith CCCP (20M) for 6 h, stainedwithMitoTracker
(red), fixed, and immunostained against cytochrome c (green). Merged confo-
cal fluorescence images are shown. Top, overview (scale bar, 20m); bottom,
indicated box (scale bar, 10 m). b, HeLa cells and human fibroblasts were
treated with CCCP (20 M) for 6 h, and total cell extracts were subjected to
Western blottingwithOPA1 antibodies. c,HeLa cells were treated or notwith
CCCP (20 M) for 30 min, and total cell lysates were subjected to Western
blotting with the indicated antibodies. d, pulse-chase experiment. HeLa cells
were subjected to radioactive labeling of newly synthesized proteins. After
labeling cellswerewashed, incubated for the indicated time in the absenceof
radiolabeled amino acids (chase) either in the presence or the absence of
CCCP (20 M). Cells were lysed at indicated times of chase and subjected to
immunoprecipitation with antibodies raised against OPA1. Elution fractions
were analyzed by digital autoradiography (top panel), and the same mem-
branewas subjected toWestern blot analysis using Opa1 antibodies (bottom
panel). The different Opa1 isoforms are indicated by arrows and named L1-,
L2-, S3-, S4-, and S5-OPA1. e, inhibition of OPA1 processing. HeLa cells were
preincubated for 10 min with or without the indicated protease inhibitors
prior to addition of CCCP (20 M) or incubation without CCCP, incubated for
25 min, harvested, lysed, and analyzed by Western blotting with OPA1 anti-
bodies. o-Phe, mM o-phenanthroline; PMSF, phenylmethylsulfonyl fluoride.
f, OPA1 processing takes place within mitochondria. HeLa cells were treated
or not with CCCP (20 M) for 30 min, harvested, and subjected to subcellular
fractionation. Equal portions of the mitochondrial fraction (M) and of the
cytosolic fraction (C) were analyzed by SDS-PAGE and immunoblotted for the
indicatedproteins. g,membrane association ofOPA1 isoforms. Isolatedmito-
chondria (100 g) from HeLa cells treated with CCCP for 30 min (right) or
untreated (left)wereextractedeitherwith30or 500mMKCl after sonicationor
with 0.1 M sodium carbonate (pH 11). Pellets were recovered by centrifuga-
tion, and 25%of each fraction, pellet (P), and supernatant (S) was analyzed by
SDS-PAGE and immunoblotted for the indicated proteins. hMia40, a soluble
protein of the intermembrane space, serves as control.
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tively, could explain these earlier observations. The protein
synthesis inhibitor cycloheximide (CHX) did not interfere with
fragmentation and OPA1 processing (Fig. 5, a–c). This indi-
cates that fragmentation of mitochondria and activation of
OPA1 cleavage are independent of protein synthesis. However,
recovery of a tubular mitochondrial network as well as the par-
allel reappearance of larger OPA1 isoforms was impaired in the
presence of CHX (Fig. 5, a–c). Therefore, mitochondrial frag-
mentation and the shift of OPA1 isoforms are not reversible
without ongoing protein synthesis consistent with the explana-
tion that a proteolytic inactivation of OPA1 causes mitochon-
drial fragmentation.
To show the causal and specific role of OPA1 in this process,
we decided to check whether OPA1 overexpression can block
uncoupler-induced fragmentation. Indeed, fragmentation of
mitochondria after CCCP treat-
ment was largely prevented upon
overexpression of OPA1 (Fig. 6, a
and b). This suggests that OPA1 is
directly involved in the fragmentation
of mitochondria induced after loss of
the mitochondrial membrane poten-
tial. A similar effect was observed
after the expression of a dominant-
negative variant of DRP1 (DRP1K38E)
that prevents fission of mitochondria
(Fig. 6, a and b). To check whether
overexpression ofOPA1 or of a dom-
inant-negative variant of DRP1
(DRP1K38E) affects the rate of
uncoupler-induced conversion of
large OPA1 isoforms into smaller
OPA1 isoforms, we performed a
pulse-chase experiment. Indeed,
overexpression of OPA1 slowed
down the processing of OPA1 as
indicated by the prolonged presence
of L1- and L2-OPA1when compared
with the control overexpression of
GFP or of DRP1K38E (Fig. 6c). This
effect may even be underestimated
also because endogenousOPA1 from
about 50% of nontransfected cells
contributes to the signal. Thus, addi-
tional expression of large isoforms of
OPA1 blocks CCCP-induced mito-
chondrial fragmentation consistent
with the proposed fusion-promoting
activity of a large but not a short
OPA1 isoform (43).Adominant-neg-
ative variant of DRP1 (DRP1K38E)
doesnot affect the rate ofOPA1proc-
essing but blocks mitochondrial frag-
mentation (Fig. 6, a–c). Thus, the
fragmentation that occurs by a block
of mitochondrial fusion depends on
the normal DRP1-dependent fission
pathway. However, processing of
OPA1 appears to occur independently from ongoing mitochon-
drial fission.
DISCUSSION
The processes of mitochondrial damage leading to dysfunc-
tion, breakdown of mitochondrial bioenergetic competence,
and mitochondrial fragmentation are linked through a cascade
of reactions. Herewe have identified a centralmolecular player,
namelyOPA1, that links changes inmitochondrialmorphology
with mitochondrial dysfunction. Our conclusions are based on
a wide variety of established model systems and patient mate-
rial exemplary for MERRF, MELAS, mtDNA depletion syn-
drome, dilated cardiomyopathy, diseases with respiratory defi-
ciencies of unknown origin, and aging. We put forward an
hypothesis that describes how this cascade is organized. Mito-
FIGURE 5.Proteolytic processing and resynthesis of largeOPA1 isoforms parallel dynamic changes of
mitochondrial morphology. Cells were treated or not (Control) with CCCP (20 M) for 30 min, washed,
and incubated with medium lacking CCCP for the indicated time periods, or CCCP (20 M) was left for 6 h.
In parallel, these experiments were performed in the presence of CHX (175g/ml). Cells were stained with
MitoTracker (red), fixed, and immunostained with cytochrome c antibodies (green). a, merged confocal
fluorescence images are shown. Top, overview (scale bar, 20m); bottom, indicated box (scale bar, 10m).
b, quantification of mitochondrial morphology as in Fig. 1b. c, OPA1 isoforms in Western blot analysis of
total cell extracts. Extracts of untreated cells (C) and of cells treated for 6 h with cycloheximide alone
(CHX 6 h) were used as controls.
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chondrial dysfunction leads to impairment of bioenergetic
competence of mitochondria. This results in reduced mem-
brane potential and ATP production. In such compromised
mitochondria, a proteolytic processing of large to small iso-
forms of OPA1 is activated. As a consequence, fusion of mito-
chondria is blocked, and due to ongoing mitochondrial fission
dysfunctionalmitochondria are segregated from the network of
intact mitochondria.
A key element of the mechanism proposed here is the regu-
latory inactivation of fusion-promoting OPA1 by proteolytic
cleavage. In the case of the homolog of OPA1 in yeast, Mgm1,
lack of either of the proteolytically generated large or small
isoforms leads to impairment of mitochondrial fusion (35, 36,
44). We propose that, in a similar way, loss of the two larger
isoforms of OPA1 in humans leads to a deficiency inmitochon-
drial fusion. This is strongly supported by the following obser-
vations. 1) OPA1 is required for mitochondrial fusion (27–29).
2) Mitochondrial fusion is blocked after treatment with uncou-
pler in vivo and in vitro (23, 25, 26, 43, 45). 3) Both OPA1
processing after uncoupler treatment as well as resynthesis of
OPA1 after removal of uncoupler occur in the same time frame
as fragmentation and refusion of mitochondria. 4) Overexpres-
sion of OPA1 blocks uncoupler-induced fragmentation of
mitochondria and slows down processing of large OPA1 iso-
forms. 5) In particular, the large isoform of OPA1 but not the
short isoformwas shown to promotemitochondrial fusion (43).
In yeast,mitochondrial dysfunction causes a deficiency in the
import of theMgm1 precursor. Consequently, formation of the
small isoform and mitochondrial fusion are impaired (36). In
humans, mitochondrial dysfunction is sensed in a different
fashion, which is independent of protein synthesis and conse-
quently protein import intomitochondria. Still, this leads to the
specific, rapid, and intramitochondrial inactivation of the
orthologous effector protein, OPA1.
We propose that this fast and sensitive molecular mecha-
nism that connects mitochondrial functionality and morphol-
ogy separates dysfunctional from functional mitochondria.
This servesmainly two purposes highly relevant to the progres-
sion of mitochondrial diseases and neurodegenerative disor-
ders. First, it would reduce further damaging of mtDNA by
reactive oxygen species by the spatial separation of damaged
mitochondria from the intact tubular network. Second, it
would enable the removal of dysfunctional mitochondria by
autophagy or more specifically mitophagy. In principle, mito-
phagy was shown to be increased in some systems ofmitochon-
drial dysfunction (46–48).OPA1-dependent counter-selection
of damaged mitochondria is an intracellular process that does
not depend on cell division-based selection. It is therefore of
particular importance in the aging process and in post-mitotic
tissues. Indeed, predominantly these tissues are affected in
myopathies and neurodegenerative disorders caused by mito-
chondrial dysfunction. Interestingly, mutations in OPA1 are
known to be causative to hereditary optic atrophy type 1 (10,
11). Therefore, impairment of OPA1 function may result in
impaired separation of damaged mitochondria contributing to
the pathomechanism of this neurodegenerative disorder. This,
however, does not exclude that impairment of mitochondrial
fusion leads to a reduced mitochondrial membrane potential,
low respiration rate, slow cell growth, and increased suscepti-
bility to apoptosis by other mechanisms as proposed earlier
(29).
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